Click Here for 5% Off Your First Aladdin Purchase!

(R)-Lisofylline - 98%, high purity , CAS No.100324-81-0

  • Moligand™
  • ≥98%
Item Number
R341807
Grouped product items
SKUSizeAvailabilityPrice Qty
R341807-2mg
2mg
In stock
$332.90
R341807-5mg
5mg
In stock
$692.90
R341807-10mg
10mg
In stock
$1,137.90
R341807-25mg
25mg
In stock
$2,276.90
R341807-50mg
50mg
In stock
$3,612.90

an immunomodulator and metabolite of Pentoxifyline, it inhibits phosphatidic acid production

Basic Description

Synonyms(R)-Lisofylline|LISOFYLLINE|100324-81-0|ProTec|CT 1501R|CT-1501R|Lisophylline|1-[(5R)-5-hydroxyhexyl]-3,7-dimethylpurine-2,6-dione|Lisofylline, (r)-|1-[(R)-5-hydroxyhexyl]theobromine|(R)-Lisophylline|3,7-Dihydro-1-[(5R)-5-hydroxyhexyl]-3,7-dimethyl-1H-pur
Specifications & PurityMoligand™, ≥98%
Storage TempStore at -20°C,Argon charged
Shipped InIce chest + Ice pads
GradeMoligand™
Product Description

(R)-Lisofylline is an immunomodulator and a major metabolite of Pentoxifylline and Methylxanthine. (R)-Lisofylline inhibits production of phosphatidic acid during the inflammatory response.

Product Properties

pKapKₐ: 0.51 (Predicted)

Associated Targets

ALB Tchem Serum albumin 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

IUPAC Name 1-[(5R)-5-hydroxyhexyl]-3,7-dimethylpurine-2,6-dione
INCHI InChI=1S/C13H20N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8-9,18H,4-7H2,1-3H3/t9-/m1/s1
InChi Key NSMXQKNUPPXBRG-SECBINFHSA-N
Canonical SMILES CC(CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C)O
Isomeric SMILES C[C@H](CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C)O
PubChem CID 501254
Molecular Weight 280.32

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

5 results found

Lot NumberCertificate TypeDateItem
C2301297Certificate of AnalysisSep 08, 2022 R341807
C2301298Certificate of AnalysisSep 08, 2022 R341807
C2301299Certificate of AnalysisSep 08, 2022 R341807
C2301302Certificate of AnalysisSep 08, 2022 R341807
C2301317Certificate of AnalysisSep 08, 2022 R341807

Chemical and Physical Properties

SolubilitySoluble in ethanol (~25 mg/ml), DMSO (~20 mg/ml), DMF (~15 mg/ml), chloroform, and methanol.
SensitivityMoisture sensitive
Refractive Indexn20D1.62 (Predicted)
Specific Rotation[α]α20/D -6.26°, c = 1 in methanol
Boil Point(°C)511.2° C at 760 mmHg (Predicted)
Melt Point(°C)105-107° C

Related Documents

References

1. Yang Z, Chen M, Carter JD, Nunemaker CS, Garmey JC, Kimble SD, Nadler JL.  (2006)  Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes..  Biochem Biophys Res Commun,  344  (3): (1017-22).  [PMID:16643856]
2. Cui P, Macdonald TL, Chen M, Nadler JL.  (2006)  Synthesis and biological evaluation of lisofylline (LSF) analogs as a potential treatment for Type 1 diabetes..  Bioorg Med Chem Lett,  16  (13): (3401-5).  [PMID:16650991]
3. Tersey SA, Carter JD, Rosenberg L, Taylor-Fishwick DA, Mirmira RG, Nadler JL.  (2012)  Amelioration of type 1 diabetes following treatment of non-obese diabetic mice with INGAP and lisofylline..  J Diabetes Mellitus,  (2): (251-257).  [PMID:26473085]
4. Rice GC, Rosen J, Weeks R, Michnick J, Bursten S, Bianco JA, Singer JW.  (1994)  CT-1501R selectively inhibits induced inflammatory monokines in human whole blood ex vivo..  Shock,  (4): (254-66).  [PMID:7735959]

Solution Calculators